HER2 insertion YVMA mutant lung cancer : long natural history and response to afatinib

Bob T. Li; Adrian Lee; Sandra O'Toole; Wendy Cooper; Bing Yu; Jamie E. Chaft; Maria E. Arcila; Mark G. Kris; Nick Pavlakis

doi:10.1016/j.lungcan.2015.10.025

HER2 insertion YVMA mutant lung cancer : long natural history and response to afatinib

Bob T. Li
, Adrian Lee
, Sandra O'Toole
, Wendy Cooper
, Bing Yu
, Jamie E. Chaft
, Maria E. Arcila
, Mark G. Kris
, Nick Pavlakis

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.

Original language	English
Pages (from-to)	617-619
Number of pages	12
Journal	Lung Cancer
Volume	90
Issue number	3
DOIs	https://doi.org/10.1016/j.lungcan.2015.10.025
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

HER, 2 protein
cancer
lungs
mutation

Access to Document

10.1016/j.lungcan.2015.10.025

Cite this

@article{6fea4f62d5094ff0809787613b37e43c,

title = "HER2 insertion YVMA mutant lung cancer : long natural history and response to afatinib",

abstract = "Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775\_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.",

keywords = "HER, 2 protein, cancer, lungs, mutation",

author = "Li, \{Bob T.\} and Adrian Lee and Sandra O'Toole and Wendy Cooper and Bing Yu and Chaft, \{Jamie E.\} and Arcila, \{Maria E.\} and Kris, \{Mark G.\} and Nick Pavlakis",

year = "2015",

doi = "10.1016/j.lungcan.2015.10.025",

language = "English",

volume = "90",

pages = "617--619",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - HER2 insertion YVMA mutant lung cancer : long natural history and response to afatinib

AU - Li, Bob T.

AU - Lee, Adrian

AU - O'Toole, Sandra

AU - Cooper, Wendy

AU - Yu, Bing

AU - Chaft, Jamie E.

AU - Arcila, Maria E.

AU - Kris, Mark G.

AU - Pavlakis, Nick

PY - 2015

Y1 - 2015

N2 - Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.

AB - Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.

KW - HER, 2 protein

KW - cancer

KW - lungs

KW - mutation

UR - http://handle.uws.edu.au:8081/1959.7/uws:32601

U2 - 10.1016/j.lungcan.2015.10.025

DO - 10.1016/j.lungcan.2015.10.025

M3 - Article

SN - 0169-5002

VL - 90

SP - 617

EP - 619

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

HER2 insertion YVMA mutant lung cancer : long natural history and response to afatinib

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this